Development of a new G-CSF product based on biosimilarity assessment.
about
Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patientsGranulocyte colony-stimulating factor (G-CSF) increases histone-complexed DNA plasma levels in healthy volunteers.Use of biosimilar filgrastim compared with lenograstim in autologous haematopoietic stem-cell transplant and in sibling allogeneic transplant.Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics.Biosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre.Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein productsZarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric studyA phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients.Confirmation of Biosimilarity in a Pharmacokinetic/Pharmacodynamic Study in Healthy Volunteers for an Analytically Highly Similar Pegfilgrastim.Clinical trials for authorized biosimilars in the European Union: a systematic review.Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors.Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors.Clinical development of biosimilars: an evolving landscape.Clinical experience with Zarzio® in Europe: what have we learned?Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia.Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte-colony-stimulating factor: safety, efficacy, and graft performance.Biosimilar medicines in oncology: single-center experience with biosimilar G-CSF.Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).Follow-on biologics in oncology - the need for global and local regulations.Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation.Biosimilar rhG-CSFs: how similar are they?Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia.Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz.Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.Product Development and Commercialization of Diagnostic or Life Science Products for Scientists and Researchers.Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF.Effectiveness of originator (Neupogen) and biosimilar (Zarzio) filgrastim in autologous peripheral blood stem cell mobilization in adults with acute myeloid leukemia: a single-center retrospective study.First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony- stimulating factorComparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers
P2860
Q24198118-7B9D3E3C-73D3-45C5-A3B3-2E03A92E3102Q33599967-932FB5CC-23CB-4C78-91D4-82F8F1A0218BQ35192785-BBE0939B-D03A-4DF7-9B16-3A5FBAFB8892Q35547653-2804B2DF-F0CB-4B5E-A1F7-D897E589641FQ35835005-0EA8275A-AB6D-4895-8017-42DC9619B253Q36000209-F6FE0914-E8BE-4686-AD98-A7800FA7B2B0Q36348464-9BF89496-4D9F-4995-BC0C-D5C2490241EBQ36411858-8F60D939-61C2-4123-B415-CF68A4BC8CC6Q36723952-D226D74C-8D3D-476E-B23F-57892C513508Q37320677-2F1C5651-46E1-4218-8B33-F62D7EFEF139Q37391741-90936646-723A-40D1-B1D6-0AC7B26D04C2Q37399588-63BE1209-447A-42E5-A335-F086532AAE2DQ37931905-89317E68-C6B6-4144-8003-AF3AC640E6C3Q38082542-1A731740-BD82-42CD-992D-0D4B96BDEA4DQ38083094-904900FB-D9D0-4FA2-B09F-16BB3AC940D2Q38125609-76AE6A35-836A-407E-95E0-D011CCD47EC6Q38269589-001D8038-88B3-4672-8158-0166111E0A65Q39385304-45C235F7-D328-4580-A7FE-617B24BF63C9Q39643433-604AF138-414C-42ED-8D12-723FF33661DAQ40141879-13845079-73C2-436E-ADFB-07040F2B8CBBQ43121123-B427E33B-F5B7-4EC7-A7AF-8895A42C64C1Q44894394-F12FBB4A-AB23-473A-975C-62E57EBED060Q45788056-E4BFBBEF-3952-4FEB-898B-637D4724CF88Q47213188-BD6EF7DB-CAA8-4599-916A-929D65E6C30AQ47908189-A4189916-BE10-45EA-B305-6F00A8B68A49Q47965968-5106962C-AA95-4D58-A7FC-41F6654E6D02Q50112937-00A201E5-05A7-4E64-8D9F-A5D7C6A07EB2Q50642969-3BD1376E-5337-4EFC-9759-7823B430341CQ51149892-C383F01F-2C9A-46D6-B3A5-9A4767417A52Q54652394-CF6B96C1-2D93-4857-8B3E-57A0C26F1F8BQ57217646-BA0BF4AC-DBEF-4D95-82D3-DBEA1CDC64F4Q58806308-C7FB1323-9D15-47CE-BEC4-B13B7F0DB7E1
P2860
Development of a new G-CSF product based on biosimilarity assessment.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Development of a new G-CSF product based on biosimilarity assessment.
@en
Development of a new G-CSF product based on biosimilarity assessment.
@nl
type
label
Development of a new G-CSF product based on biosimilarity assessment.
@en
Development of a new G-CSF product based on biosimilarity assessment.
@nl
prefLabel
Development of a new G-CSF product based on biosimilarity assessment.
@en
Development of a new G-CSF product based on biosimilarity assessment.
@nl
P2093
P2860
P356
P1433
P1476
Development of a new G-CSF product based on biosimilarity assessment.
@en
P2093
M Kinzig-Schippers
M Muenzberg
P2860
P304
P356
10.1093/ANNONC/MDP574
P577
2009-12-17T00:00:00Z